By Epocrates
Report updated Apr 17, 2026
epocrates: Drug Info & Pill ID
For u.S.-based healthcare professionals including physicians (MDs/DOs), nurse practitioners, physician associates, pharmacists, and medical students.
epocrates: Drug Info & Pill ID is a challenged medical app that is free with in-app purchases. With a 3.0/5 rating from 33.4K reviews, it faces significant user friction. Users particularly appreciate clinical utility, though aggressive monetization remains a common concern.
What is epocrates: Drug Info & Pill ID?
Current Momentum
v26.4 · 1w ago
MaintenanceThe app is currently in maintenance mode, with the most recent updates limited to general bug fixes and performance improvements.
Active Nemesis
MDCalc Medical Calculator
By MD Aware
Other Rivals
7-Day Rank Pulse 🇺🇸
MedicalNo ranking data
Rating Pulse 🇺🇸
Recent User MoodAI-powered deep analysis surfacing high-signal insights. Still in beta, accuracy improves daily. For informational purposes only.
What makes this app unique?
What Does It Look Like?
How Is The App's Momentum Right Now?
Loading...
What Are The Key Features?
Simultaneously check interactions for up to 30 medications
Visual tool to identify pills by imprint, shape, color, or image
Full functionality available without internet connectivity
How much does it cost?
- Free base version with core clinical tools
- Premium upgrade (Epocrates+) via in-app purchase
The app has recently moved toward aggressive gating of core drug data, limiting free users to as few as 1-2 views per week, which is driving significant negative sentiment among long-term professional users.
Who Built It?
Providing U.S. healthcare professionals with point-of-care clinical decision support tools to improve prescribing safety and efficiency.
Portfolio
1
Apps
Who is Epocrates?
Epocrates occupies a dominant legacy position in the U.S. clinical reference space, leveraging a high-intent professional user base to maintain a top-grossing status. Its primary moat is deep institutional trust and long-standing integration into clinical workflows, which creates high switching costs despite emerging competition. However, the publisher is currently navigating a strategic inflection point where aggressive monetization of premium tiers and reported stability issues are creating friction with its core medical audience.
Who is Epocrates for?
- U.S.-based healthcare professionals
- Physicians
- Nurse practitioners
- Pharmacists requiring rapid drug information at the point of care
Portfolio momentum
Maintains an intense development cadence with 11 updates in the last 6 months for its single flagship medical reference title.
What do users think recently?
High confidence · Latest 100 of 119 total reviews analyzed · Based on 119 reviews. Signal may be noisy.
How did the latest release land?
What is the recent mood?
Recent user voice shows a frustrated sentiment. Users appreciate clinical utility, but report aggressive monetization and critical stability issues.
What Users Love
What Frustrates Users
What is the competitive landscape for epocrates: Drug Info & Pill ID?
How's The Medical Market?
How does it evolve in the Medical market?
| Country | Category | Chart | Rank | Change |
|---|---|---|---|---|
| 🇺🇸 US | Medical | AndroidGrossing | #1 | |
| 🇺🇸 US | Medical | iOSGrossing | #1 |
The rivals identified
The Nemesis
MDCalc Medical Calculator
★4.9 (51.2K)MD Aware, LLC
🚀MDCalc matches the target's scale (51k vs 33k ratings) and high-frequency utility, serving as the primary alternative for clinical decision-making tools.
Head to Head
The target app should defend its position by deepening its 'Calculators' sub-feature to match MDCalc's evidence-based summaries, while leveraging its superior Pill ID and interaction tools as the primary 'safety' differentiator.
What sets epocrates: Drug Info & Pill ID apart
Integrated Pill ID tool and multi-drug interaction checker for bedside safety—features entirely absent from MDCalc.
Comprehensive drug reference database (6,000+ drugs) providing a broader utility for pharmacists and prescribing clinicians.
What's MDCalc Medical Calculator's Edge
Superior depth in clinical formulas (e.g., CHADS2, GFR, Wells' Criteria) with direct links to supporting PubMed literature.
Optimized 'calculator-first' UX that allows for faster data entry for risk scores compared to the target's multi-step navigation.
Contenders
UpToDate
★4.3 (11.3K)UpToDate, Inc.
🚀A high-authority clinical reference with 11k+ ratings and a consistent release cadence (6 in 6 months).
Offers comprehensive disease management and graded treatment recommendations vs. target's focus on drug-specific dosing.
Includes patient education materials and 'What's New' clinical updates that go beyond the target's reference utility.
Calculate by QxMD
★4.5 (13.2K)WebMD
📈A direct utility rival with 13k+ ratings, backed by the WebMD ecosystem.
Features a 'Point-of-Care' toolset that integrates with institutional library access for full-text research.
Focuses on 'Decision Support' workflows that compete directly with the target's clinical calculator module.
Read by QxMD
★4.8 (6K)WebMD
🚀High innovation signal with 7 releases in the last 6 months and a focus on medical literature discovery.
Provides a personalized feed of new medical journal articles vs. the target's static reference database.
Optimized for PDF management and institutional login integration for academic clinicians.
DynaMed
★4.9 (3.5K)EBSCO Publishing
📈Strong clinical decision support alternative with a high rating (4.87) and active maintenance.
Employs a strict evidence-based methodology for disease summaries, updated daily to reflect new trials.
Positioned for institutional hospital use with deep integration into EBSCO databases.
Peers
Doximity
★4.8 (191.5K)Doximity
⚡While a social network, its massive scale (191k ratings) and 24 releases in 6 months make it a dominant presence on clinician home screens.
Provides HIPAA-secure faxing and a 'Dialer' for patient calls, capturing the 'workflow' time the target app competes for.
Professional networking and career management focus vs. the target's purely clinical utility.
5 Minute Clinical Consult
★4.8 (3.1K)Unbound Medicine, Inc.
⚡Directly targets the 'busy clinician' persona with a similar 'quick-glance' value proposition.
Structured specifically for 30-second lookups during patient encounters.
Focuses on diagnosis and treatment algorithms rather than drug-specific monographs.
Skyscape Medical Library
★4.8 (3K)Skyscape Medpresso Inc
🚀Acts as an aggregator for multiple medical resources, including drug guides.
Modular 'Library' approach allowing users to purchase and stack different medical texts in one UI.
Includes 'SmartLink' technology to cross-reference between different medical books.
Merck Manual Professional
★4.8 (999)Merck & Co Inc
🚀A legacy reference standard that remains highly rated and recently updated.
Completely free, high-quality clinical content without the subscription model used by the target's premium tiers.
Includes procedural videos and 3D anatomical models not found in the target app.
New Kids on the Block
Figure 1 - Medical Cases
★4.1 (13.5K)Figure 1, Inc.
⚡An emerging threat focusing on visual/case-based learning with a very recent update (April 2026).
Crowdsourced 'Visual Case' sharing for rare diseases, providing a real-world diagnostic layer the target's static data lacks.
Focuses on peer-to-peer collaboration and 'medical curiosity' rather than just reference lookup.
The outtake for epocrates: Drug Info & Pill ID
Strengths to defend, gaps to attack
Core Strengths
- Market-leading brand with 2M+ prescribers
- Unique 30-drug interaction checker and visual Pill ID
- Full offline database functionality
Critical Frictions
- Critical crashing bugs in v26.4.0 (iOS)
- Severe Android performance gap (2.65 rating)
- Restrictive 'free view' limits on core drug data
Growth Levers
- Add evidence-based summaries to calculators to match MDCalc
- Integrate patient education materials to compete with UpToDate
- Develop visual case-sharing features to counter Figure 1
Market Threats
- User migration to free resources like Merck Manual
- Competitors offering superior UX for clinical formulas (MDCalc)
- Loss of legacy professional users due to monetization shifts
What are the next best moves?
Immediate Hotfix for iOS v26.4.0
Top complaint theme is 'Critical Stability Issues' where the app crashes on load, rendering it unusable for clinicians.
Re-evaluate 'Free View' Limits
Sentiment data shows a 'declining' trend driven by users abandoning the app after being limited to 1-2 drug views per week.
Enhance Calculator Evidence
Competitor MDCalc wins on providing 'Next Steps' and PubMed links for every calculation, a feature gap in the current epocrates offering.
Feature Gaps vs Competitors
- Evidence-based clinical decision rules and PubMed links (available in MDCalc)
- Patient education materials (available in UpToDate)
- Visual/case-based crowdsourced learning (available in Figure 1)
- Procedural videos and 3D anatomical models (available in Merck Manual)
Key Takeaways
epocrates remains a revenue powerhouse as the #1 Grossing medical app, but it is currently burning user trust through a combination of critical stability failures and an overly restrictive paywall. To maintain its market lead, the PM must prioritize technical reliability and find a monetization balance that doesn't block the core utility of drug lookups for daily clinical practice.
Where Is It Heading?
Declining
v26.4.0 update causing immediate crashes on iOS — critical stability failure for point-of-care tool.
Upset user base due to new 'free view' limits — high risk of churn to free alternatives.
Recent updates focused on maintenance rather than feature expansion, while competitors like Figure 1 are innovating in case-based learning.